Assembling synergistic peptide-drug conjugates for dual-targeted treatment of cancer metastasis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Chemical Synthesis and Analysis · Peptidase Inhibition and Analysis · Click Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Supramolecular assembly of peptide amphiphiles10.1021/acs.accounts.7b00297 ↗
2. Molecular engineering solutions for therapeutic peptide delivery10.1039/C7CS00536A ↗
3. Self-assembled peptide-based nanomaterials for biomedical imaging and therapy10.1002/adma.201703444 ↗
4. Peptide‐based multifunctional nanomaterials for tumor imaging and therapy10.1002/adfm.201804492 ↗
5. Hierarchically oriented organization in supramolecular peptide crystals10.1038/s41570-019-0129-8 ↗
6. Biomimetic peptide self-assembly for functional materials10.1038/s41570-020-0215-y ↗
7. Enzymatic noncovalent synthesis10.1021/acs.chemrev.0c00306 ↗
8. Peptide-based supramolecular systems chemistry10.1021/acs.chemrev.1c00089 ↗
9. Self-assembling prodrugs10.1039/C7CS00521K ↗
10. Peptide-drug conjugates with different linkers for cancer therapy10.1021/acs.jmedchem.0c01530 ↗
11. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)10.1039/D0CS00556H ↗
12. Peptide-drug conjugate-based nanocombination actualizes breast cancer treatment by maytansinoid and photothermia with the assistance of fluorescent and photoacoustic images10.1021/acs.nanolett.9b00770 ↗
13. From nanofibers to nanorods: nanostructure of peptide-drug conjugates regulated by polypeptide-PEG derivative and enhanced antitumor effect
14. Assemblies of peptide-cytotoxin conjugates for tumor-homing chemotherapy
15. Improved antiglioblastoma activity and BBB permeability by conjugation of paclitaxel to a cell-penetrative MMP-2-cleavable peptide10.1002/advs.202001960 ↗
16. Shuttling of peptide-drug conjugates by G protein-coupled receptors is significantly improved by pulsed application10.1002/cmdc.202000490 ↗
17. Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency10.1016/j.biomaterials.2021.121139 ↗
18. Multifunctional supramolecular filament hydrogel boosts anti‐inflammatory efficacy in vitro and in vivo10.1002/adfm.202109173 ↗
19. Enzymatic self-assembly confers exceptionally strong synergism with NF-κB targeting for selective necroptosis of cancer cells10.1021/jacs.7b12368 ↗
20. Self-assembled nanostructures regulate H2S release from constitutionally isomeric peptides10.1021/jacs.8b09320 ↗
21. Proline isomerization-regulated tumor microenvironment-adaptable self-assembly of peptides for enhanced therapeutic efficacy10.1021/acs.nanolett.9b03136 ↗
22. Elastase-triggered H2S delivery from polymer hydrogels10.1039/C9CC08752D ↗
23. Controlled supramolecular assembly inside living cells by sequential multistaged chemical reactions10.1021/jacs.0c05261 ↗
24. Enzymatic assemblies of thiophosphopeptides instantly target golgi apparatus and selectively kill cancer cells10.1002/anie.202102601 ↗
25. Structure-based programming of supramolecular assemblies in living cells for selective cancer cell inhibition10.1002/anie.202103507 ↗
26. Supramolecular antagonists promote mitochondrial dysfunction10.1021/acs.nanolett.1c01469 ↗
27. Noncanonical amino acids for hypoxia-responsive peptide self-assembly and fluorescence10.1021/jacs.1c06435 ↗
28. Supramolecular nanostructures formed by anticancer drug assembly10.1021/ja3115983 ↗
29. Peptide–drug conjugates as effective prodrug strategies for targeted delivery10.1016/j.addr.2016.06.015 ↗
30. The role of critical micellization concentration in efficacy and toxicity of supramolecular polymers10.1073/pnas.1913655117 ↗
31. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel10.1038/s41551-020-0597-7 ↗
32. Supramolecular tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy10.1021/acsnano.0c03286 ↗
33. Supramolecular design of unsymmetric reverse bolaamphiphiles for cell-sensitive hydrogel degradation and drug release10.1002/anie.201913087 ↗
34. The current state of peptide drug discovery: back to the future?10.1021/acs.jmedchem.7b00318 ↗
35. Trends in peptide drug discovery10.1038/s41573-020-00135-8 ↗
36. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect10.1016/j.addr.2010.04.009 ↗
37. Carrier-free nanomedicines for cancer treatment10.1016/j.pmatsci.2021.100919 ↗
38. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells10.1038/sj.onc.1207999 ↗
39. High resolution crystal structures of the p120 RasGAP SH3 domain10.1016/j.bbrc.2006.12.044 ↗
40. Measurement of the beta-sheet-forming propensities of amino acids10.1038/367660a0 ↗
41. Phosphoinositide regulation of the actin cytoskeleton10.1146/annurev.physiol.65.092101.142517 ↗
42. TAT-RasGAP317-326 kills cells by targeting inner-leaflet-enriched phospholipids10.1073/pnas.2014108117 ↗
43. Disulfide-cleavage-triggered chemosensors and their biological applications10.1021/cr300358b ↗
44. How Taxol stabilises microtubule structure10.1016/S1074-5521(99)89002-4 ↗
45. A perspective on cancer cell metastasis10.1126/science.1203543 ↗
46. Emerging biological principles of metastasis10.1016/j.cell.2016.11.037 ↗
47. Cancer progression and the invisible phase of metastatic colonization10.1038/s41568-020-00300-6 ↗
48. Actin-microtubule crosstalk in cell biology10.1038/s41580-018-0067-1 ↗
49. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages10.1016/j.addr.2021.113909 ↗
50. G.D. Fasman, Springer, 1996.
51. S. Krimm, American Chemical Society: Washington, DC, 1999.
52. The use of Nile Red to monitor the aggregation behavior in ternary surfactant-water-organic solvent systems10.1002/poc.919 ↗
53. Inhibition of cell migration and invasion mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor10.1038/onc.2013.465 ↗
54. Selective degradation of PD‐L1 in cancer cells by enzyme‐instructed self‐assembly
55. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment10.1021/nn4047925 ↗